News Article | May 11, 2017
MONROVIA, CA--(Marketwired - May 10, 2017) - Cantech Holding, Inc., formerly Reve Technologies, Inc., ( : BSSP) (the "Company" or "Cantech") a development stage immunotherapeutic based technology company today announced it has executed a Memorandum of Understanding (the "MOU") between TCM Group ("TCM") and Cantech Intl. Group Mexico ("CIGM"), a to be newly formed unit of Cantech Holding, Inc. for the construction of a manufacturing facility in the city of Tijuana B.C. Mexico. Updating the previously reported August 19, 2016 announcement, and based on several months of discussion and developments the resulting new collaborative joint venture now directly between the principle scientists entities proposes i) TCM will manufacture the specific compound T Cell Modulator and ii) CIGM will manufacture the specific compound Irreversible Pepsin Fraction to be marketed and sold as a newly combined treatment as well as for individual compound applications. All products require authorization to manufacture and sale under the health and sanitary legal framework of Mexico. Dr. Hector Zepeda Lopez on behalf of TCM, and Harry Zhabilov, CSO of Cantech Holding and on behalf of CIGM will endeavor to form a new compound from the combination of the two existing treatments, T Cell Modulator and the Irreversible Pepsin Fraction to become a registered medicine as part of the application with COFEPRIS for approval and integration into the current Human Studies of the T Cell Modulator to fast track the approval process. The primary focus of the new compound will be for inclusion in the Health Department of Mexico City "Doctor at Home Program" which has indicated the potential acceptance of Dr. Zepeda's treatment protocol. The "Doctor at Home Program" has been very successful and it is now being franchised to other government health organizations in central and South American countries. Through the joint venture the new compound would be produced for commercial sales nationwide in the United Mexican States and in other Latin American countries participating in the Doctor at Home Program spearheaded by Mexico. About Canteck Pharma, Inc. IPF for Cancer treatment Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen. Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does. IPF proteins attach to tumor antigens, creating super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition. It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them. This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent -- fraction and/or its proteins that can attach, serve as the immunogen are already known. About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.) The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico. The Company changed its name to Cantech Holding, Inc. effective on May 27, 2016 and its domicile to Wyoming from Nevada also effective on May 27, 2016. About TCM, the TCM Group, Dr. Hector Zepeda Lopez Ph. D. and Mario Rodriguez Ph.D. The collaboration and association with TCM merits a description of the principal members of the TCM group, starting with Dr. Zepeda Lopez holder of the Influenza virus H1N1 vaccine patent and developed for the 2009 pandemic outbreak in Mexico, Dr. Zepeda holds 6 Ph.Ds. and has had post-doctoral stays at Sick Children Hospital, Microbiology Section Toronto Canada,Health Science Center Molecular Biology Dept. Texas University USA, Karolinska Institute Molecular Diagnostic Dept. Stockholm Sweden, Pasteur Institute Molecular Pathogenesis Dept. Paris France and the Center of Development Vaccine Baltimore USA 1997. Also integrating the TCM group is Mario Rodriguez Ph.D. and scientist and engineer with vast experience in physic, electronic, optical technologies, state of the technology set up and manufacturing, with degrees from San Diego State University and the University of California Irvine, as well as a Ph.D. from the Imperial College in London. Mario currently participates directing the manufacturing efforts of highly specialized defense systems for several contractors, his expertise in GMP and highly specialized and regulated facilities setup and organization is of the most important usefulness in this endeavor. TCM is capable of modulating the immune response through activation of specific molecules involved in controlling innate immunity termed "toll like receptors". Clinical data has been generated in a variety of immunologically-associated conditions including multiple sclerosis, viral infections, and cancer. In vitro data demonstrates consistent production of immune modulatory cytokines including interferons and interleukins after treatment of immune cells with TCM. This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Cantech Holding, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Cantech Holding, Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Cantech Holding, Inc.'s filings with the Securities and Exchange Commission.
Kitagawa Y.,Shiga University of Medical Science |
Zhou M.,Shiga University of Medical Science |
Zhou M.,Nagahama Institute of Bio-Science and Technology |
Yamaguchi M.,Shiga University of Medical Science |
And 5 more authors.
Microbes and Infection | Year: 2010
M2-2 protein of human metapneumovirus (HMPV) is encoded by one of two overlapping open reading frames within M2 mRNA. The precise function of HMPV M2-2 protein remains unknown. We here examined effect of M2-2 protein on HMPV transcription and replication using a minigenome construct and monitoring luciferase reporter gene expression. The minigenome assays demonstrated that M2-2 protein inhibited both transcription and RNA replication. The inhibitory function of M2-2 protein was completely abrogated by removal of eight or four amino acids from its N- or C-terminus, respectively, demonstrating importance of both short terminal sequences for maintaining its functional structure. Immunoprecipitation experiments revealed interaction of M2-2 protein with L protein, which might be involved in inhibition of HMPV transcription and replication. Prior accumulation of intracellular M2-2 protein severely restrained HMPV from replicating. Thus inherent viral control of the M2-2 gene expression in infected cells seems to be essential for efficient HMPV replication. © 2009 Elsevier Masson SAS. All rights reserved.
Roda A.,University of Bologna |
Roda A.,Italian National Institute of Biosystems and Biostructures |
Mirasoli M.,University of Bologna |
Dolci L.S.,University of Bologna |
And 5 more authors.
Analytical Chemistry | Year: 2011
A simple and versatile analytical device designed to perform, even simultaneously, different types of bioassays has been developed and optimized. A transparent microfluidics-based reaction chip, where analytes were quantitatively detected by means of biospecific reactions and chemiluminescence detection, was placed in contact with a thermoelectrically cooled CCD sensor through a fiber optic taper. Such a lensless contact imaging configuration combined adequate spatial resolution and high light collection efficiency within a small size portable device. The miniaturization of the reaction chamber ensured short analysis times (in the minutes range), while the use of chemiluminescence detection provided wide signal dynamic range and high detectability, down to attomole levels of protein and femtomole levels of nucleic acid analytes. A model hybrid panel test was realized by combining an enzyme assay for alkaline phosphatase activity, a nucleic acid hybridization assay for Parvovirus B19 DNA, and an immunoassay for horseradish peroxidase as a model antigen. The successful simultaneous quantification of the three targets demonstrated that a range of analytes, from enzymes to antigens, antibodies, and nucleic acids, can be measured in a single run, thus enabling the realization of a complete, personalized diagnostic panel test for early diagnosis of a given disease and patient follow-up. © 2011 American Chemical Society.
Re M.C.,Italian National Institute of Biosystems and Biostructures |
Vitone F.,Microbiology Section |
Biagetti C.,University of Bologna |
Schiavone P.,Microbiology Section |
And 4 more authors.
Clinical Microbiology and Infection | Year: 2010
As proviral human immunodeficiency virus type 1 (HIV-1) DNA can replenish and revive viral infection upon activation, its detection might offer significant therapeutic information, complementing the input provided by plasma RNA determination in the follow-up of infected individuals. A selected group of acutely infected subjects was studied to verify both total and 2-long terminal repeat (2-LTR) DNA proviral load during the acute phase of infection and thereafter. Patients were divided in two sex- and age-matched groups: 19 naive individuals who did not receive antiretroviral therapy during the observation period and 20 subjects treated according to current guidelines. Total and 2-LTR HIV-1 DNA proviral load, in addition to RNA viral load and CD4 cell count, were determined in peripheral blood mononuclear cells (PBMC) at baseline, 6 and 12 months after the first sampling. Total and 2-LTR HIV-1 DNA proviral load exhibited no significant variation at any time in the naive patients (total HIV-1 DNA ranging from 896 ± 731 to 715 ± 673 copies/105 PBMC and 2-LTR HIV-1 DNA ranging from 94 ± 105 to 65 ± 44 copies/105 PBMC), whereas a significant reduction in both total HIV-1 DNA (ranging from 997 ± 676 to 262 ± 174 copies/105 PBMC) and 2-LTR HIV-1 DNA proviral load (ranging from 116 ± 55 to 26 ± 35 copies/105 PBMC) was detected in highly active antiretroviral therapy (HAART) patients, together with a CD4+ T cell count increase and RNA load decrease. HAART negatively affects both the labile HIV burden and the integrated proviral DNA, at least in the initial period of successful treatment, suggesting that quantification of HIV-1 DNA proviral load may be an important parameter in monitoring HIV infection. © 2009 The Authors. Journal Compilation.
Kumar V.,Microbiology Section |
Singh Solanki A.,Plant Wealth Sector |
Sharma S.,Motilal Nehru National Institute of Technology
Thai Journal of Agricultural Science | Year: 2011
The yield and nutrient uptake of Plantago ovata were studied using dual inoculation with AM fungi (Glomus fasciculatum) and Azotobacter chroococcum. The experiment was conducted for two consecutive years, with two levels of chemical fertilizers (F1: N-P-K: 24-24-32 kg ha -1) and (F2: N-P-K: 30-30-40) kg ha -1). Inoculation with the AM fungi and Azotobacter chroococcum generated encouraging results; seed yield (1120.7 kg ha -1), husk yield (297.1 kg ha -1), plant height (40.4 cm), spike plant-1 (33.6), and 1000 seeds weight (1.793 g) were highest with treatment T12 (F2 fertilizer level + both bioinoculants) followed by treatment T9 (F1 fertilizer level + both bioinoculants), T10 (F2 + A. chroococcum), T11 (F2 + AM fungi), as compared to T1 (control), T2-T4 (bioinoculants) and T5-T6 (F1 and F2 fertilizer levels). The nitrogen uptake was more in Azotobacter treated plants, while higher P and K uptake was attained in AM fungi inoculated plants. The survival count of inoculated bacteria was highest on 60 days after inoculation and declined thereafter. Economic analysis revealed the net profit from seed and husk was highest in T9 using dual inoculation of microbes with 80% of recommended dose of fertilizer followed by T12 and T10.
Centonze A.R.,Microbiology Section |
Tonolli E.,Microbiology Section |
Fontana R.,Microbiology Section
Clinical and Vaccine Immunology | Year: 2013
The performances of seven Immulite 2000 (Siemens Healthcare Diagnostics) TORCH (Toxoplasma gondii, other microorganisms, rubella virus, cytomegalovirus, and herpes simplex virus) assays were evaluated in comparison with the performances of the ETI-MAX 3000 (DiaSorin) TORCH assays. The two systems demonstrated good agreement, and given their sensitivity, specificity, and positive predictive value, they can be used with confidence for TORCH prenatal screening. Copyright © 2013, American Society for Microbiology. All Rights Reserved.
Varalakshmi S.,National Dairy Research Institute |
Kirubaharan J.J.,Microbiology Section
Research Journal of Biotechnology | Year: 2014
The effect of Cyclophosphamide (CY) on the immune status of birds was studied by administering the chickens with live Newcastle disease vaccine. Normal and immunosuppressed chickens were vaccinated with the Thermostable live Newcastle disease vaccine by ocular-nasal route at 10th day of age. The immune suppressed chickens had significantly low serum antibody titers and histopathological studies showed that there is depletion of bursal tissue in the CY treated chickens compared to CY untreated chickens. There is no significant difference in the cell mediated immunity between ablated and non ablated group. This study concludes that there is suppression of only humoral immunity by administering the cyclophosphamide and there is no effect on cell mediated immunity. CY will be used to study the role of cell mediated immunity and mucosal immunity in the absence of humoral immunity.
Dalfino L.,University of Bari |
Puntillo F.,University of Bari |
Ondok M.J.M.,University of Bari |
Mosca A.,Microbiology Section |
And 5 more authors.
Clinical Infectious Diseases | Year: 2015
Background. Critically ill patients with severe sepsis or septic shock may need relatively high colistin daily doses for efficacy against multidrug-resistant and extensively drug-resistant gram-negative rods. However, acute kidney injury (AKI) may represent a major dose-limiting adverse effect of colistin. We sought to determine AKI occurrence and to identify factors influencing AKI risk in severely ill patients receiving colistin according to a recently proposed dosing strategy. Methods. A prospective, observational, cohort study involving patients with severe sepsis or septic shock who received colistin was performed. AKI was defined according to Acute Kidney Injury Network criteria. Colistin administration was driven by a modified pharmacokinetics-pharmacodynamics (PK/PD)-based dosing approach. Results. Of 70 patients who received colistin at a median daily dose of 9 million IU (MIU; interquartile range, 5.87-11.1 MIU), 31 (44%) developed AKI. In univariate analysis, age, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA), score and baseline renal impairment were significantly associated with AKI. Moreover, patients with AKI were less frequently treated with adjuvant ascorbic acid (P =. 003). In multivariate analysis, independent predictors of AKI were baseline renal impairment (adjusted hazard ratio, 4.15; 95% confidence interval, 1.9-9.2; P <. 001) and age (1.03; 1.0-1.05; P =. 028), whereas a strong independent renal-protective role emerged for ascorbic acid (0.27;. 12-.57; P <. 001). Conclusions. In severely ill patients receiving colistin according to a PK/PD-driven dosing approach, baseline renal impairment and older age strongly predict AKI occurrence, but concomitant administration of ascorbic acid markedly reduces AKI risk, allowing safer use of colistin. © 2015 The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
Vecchiarelli A.,Microbiology Section |
d'Enfert C.,Institute Pasteur Paris
Virulence | Year: 2012
Bioluminescence imaging allows the visualization of the temporal and spatial progression of biological phenomena, in particular infection, by non-invasive methods in vivo. This nature-borrowed technology has been successfully used to monitor bacterial infections but recent studies have also succeeded in tracking fungal infections such as those caused by the two major opportunistic fungal pathogens Candida albicans and Aspergillus fumigatus. The findings of Donat and collaborators published in this issue now show that by combining the sensitivity of the Gaussia princeps luciferase with a surface display expression system it is possible to perform longitudinal infection studies on cutaneous forms of aspergillosis with a small number of animals. Besides providing new and valuable information in the field of aspergillosis, the findings of Donat et al. offer a new perspective on the general applicability of bioluminescence methodologies for eukaryotic pathogens where the bacterial lux operon cannot be exploited. © 2012 Landes Bioscience.
PubMed | Anesthesia and Intensive Care Unit, Microbiology Section and University of Bari
Type: Journal Article | Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | Year: 2015
Critically ill patients with severe sepsis or septic shock may need relatively high colistin daily doses for efficacy against multidrug-resistant and extensively drug-resistant gram-negative rods. However, acute kidney injury (AKI) may represent a major dose-limiting adverse effect of colistin. We sought to determine AKI occurrence and to identify factors influencing AKI risk in severely ill patients receiving colistin according to a recently proposed dosing strategy.A prospective, observational, cohort study involving patients with severe sepsis or septic shock who received colistin was performed. AKI was defined according to Acute Kidney Injury Network criteria. Colistin administration was driven by a modified pharmacokinetics-pharmacodynamics (PK/PD)-based dosing approach.Of 70 patients who received colistin at a median daily dose of 9 million IU (MIU; interquartile range, 5.87-11.1 MIU), 31 (44%) developed AKI. In univariate analysis, age, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA), score and baseline renal impairment were significantly associated with AKI. Moreover, patients with AKI were less frequently treated with adjuvant ascorbic acid (P = .003). In multivariate analysis, independent predictors of AKI were baseline renal impairment (adjusted hazard ratio, 4.15; 95% confidence interval, 1.9-9.2; P < .001) and age (1.03; 1.0-1.05; P = .028), whereas a strong independent renal-protective role emerged for ascorbic acid (0.27; .12-.57; P < .001).In severely ill patients receiving colistin according to a PK/PD-driven dosing approach, baseline renal impairment and older age strongly predict AKI occurrence, but concomitant administration of ascorbic acid markedly reduces AKI risk, allowing safer use of colistin.